Tim peneliti di Cancer Research Institute (CSI) Universitas Nasional Singapura parantos ngembangkeun ubar péptida novel anu disebut FFW anu tiasa nyegah pangembangan karsinoma hépatoselular (HCC) atanapi primér. kanker haté . Penemuan landmark ieu muka panto pikeun pengobatan kanker ati anu langkung efektif sareng ngirangan efek samping.
SALL4 is a protein associated with tumor growth and has been used as a prognostic marker and drug target for HCC, lung cancer and leukemia. It is usually present in a growing fetus, but is inactive in adult tissues. In some cancers, such as HCC, SALL4 is reactivated, leading to tumor tumuwuhna.
Molekul ubar anu nindak kana protéin, sapertos SALL4-NuRD, biasana meryogikeun protéin target ngagaduhan "saku" alit dina struktur 3-D na, dimana molekul ubar tiasa aya sareng fungsina. Dina panilitian awal, mendakan yén protéin SALL4 berinteraksi sareng protéin NuRD anu sanés, ngawangun kamitraan anu penting pisan pikeun pamekaran kanker sapertos HCC. SALL4 dirancang ku tim paniliti ieu henteu milari 'kantong', tapi didamel biomolekul anu ngahalangan interaksi antara SALL4 sareng NuRD. Panilitian parantos mendakan yén meungpeuk interaksi ieu tiasa nyababkeun maot sél tumor sareng ngirangan gerakan sél tumor.
FFW can effectively block protein-protein interactions, and does not require “pockets” to take effect. The research team also found that when combined with sorafenib, FFW can reduce the growth of sorafenib-resistant HCC. Although most terapi sasaran are small-molecule drugs, well-designed peptide drugs (such as FFW) tend to have higher selectivity than large-molecule surfaces and are less toxic than small molecules.
Panaliti Singapura Dr. Liu Bee Hui nyarios: Dumasar kana inpormasi anu kami peroleh tina struktur sareng éksprési gén global, urang teras-terasan diajar péptida ieu sareng péptida sanésna kalayan struktur anu sami dina antukna ngajantenkeun aranjeunna ubar kelas klinis sareng nguntungkeun penderita.
